Table 3.
Clinical PET studies using [18F]AlF-NOTA-octreotide
| Year | Study | No Participants |
Outcome | References |
|---|---|---|---|---|
| [18F]AlF-NOTA-octreotide | ||||
| 2019 | First comparison with [68Ga]Ga-DOTATATE in diffuse metastases of rectal NET | 1 | [18F]AlF-NOTA-octreotide was a promising clinical alternative for [68Ga]Ga-DOTATATE and warrants further head-to-head evaluation | Pauwels et al. (2019) |
| 2019 | Biodistribution, safety and dosimetry in healthy volunteers. Detection of neuroendocrine neoplasms (NENs) in patients |
Healthy: 3 Patients: 22 |
[18F]AlF-NOTA-octreotide was well tolerated and provided superior imaging of well-differentiated NENs. Tumour-to-background ratios were significantly higher compared to [18F]FDG | Long et al. (2019) |
| 2020 | Biodistribution, dosimetry and comparison with [68Ga]Ga-DOTATATE in NETs |
Healthy: 6 Patients: 6 |
[18F]AlF-NOTA-octreotide was safe and well tolerated. Lesion detection rate and tumour-to-background ratios were comparable to [68Ga]Ga-DOTATATE | Pauwels et al. (2020) |
| 2020 | Head-to-head comparison with [68Ga]Ga-DOTATATE in patients with NENs |
Healthy: 3 Patients: 8 |
[18F]AlF-NOTA-octreotide produces similar image quality and fine detection rate of lesions, especially in the liver, because of lower liver background uptake than [68Ga]Ga-DOTATATE | Hou et al. (2020) |